Everolimus (RAD001): first systemic treatment for subependymal giant cell astrocytoma associated with tuberous sclerosis complex
出版年份 2012 全文链接
标题
Everolimus (RAD001): first systemic treatment for subependymal giant cell astrocytoma associated with tuberous sclerosis complex
作者
关键词
-
出版物
Future Oncology
Volume 8, Issue 12, Pages 1515-1523
出版商
Future Medicine Ltd
发表日期
2012-12-12
DOI
10.2217/fon.12.146
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Biomarker Development for the Clinical Activity of the mTOR Inhibitor Everolimus (RAD001): Processes, Limitations, and Further Proposals
- (2014) Terence O'Reilly et al. Translational Oncology
- Surgical resection of subependymal giant cell astrocytomas (SEGAs) and changes in SEGA-related conditions: a US national claims database study
- (2012) Peter Sun et al. CURRENT MEDICAL RESEARCH AND OPINION
- Outcomes of resecting subependymal giant cell astrocytoma (SEGA) among patients with SEGA-related tuberous sclerosis complex: a national claims database analysis
- (2012) Peter Sun et al. CURRENT MEDICAL RESEARCH AND OPINION
- Everolimus alters white matter diffusion in tuberous sclerosis complex
- (2012) J.-M. Tillema et al. NEUROLOGY
- Ovarian Toxicity from Sirolimus
- (2012) Matthias Braun et al. NEW ENGLAND JOURNAL OF MEDICINE
- Effective everolimus treatment of inoperable, life-threatening subependymal giant cell astrocytoma and intractable epilepsy in a patient with tuberous sclerosis complex
- (2011) Marta Perek-Polnik et al. EUROPEAN JOURNAL OF PAEDIATRIC NEUROLOGY
- Research and innovation in the development of everolimus for oncology
- (2011) David Lebwohl et al. Expert Opinion on Drug Discovery
- Rapamycin passes the torch: a new generation of mTOR inhibitors
- (2011) Don Benjamin et al. NATURE REVIEWS DRUG DISCOVERY
- Tuberous Sclerosis Complex: Neurological, Renal and Pulmonary Manifestations
- (2011) D. N. Franz et al. NEUROPEDIATRICS
- Regression of subependymal giant cell astrocytomas with RAD001 (Everolimus) in tuberous sclerosis complex
- (2010) Michal Yalon et al. CHILDS NERVOUS SYSTEM
- Tuberous sclerosis complex: tumors and tumorigenesis
- (2010) Julita Borkowska et al. INTERNATIONAL JOURNAL OF DERMATOLOGY
- Everolimus for Subependymal Giant-Cell Astrocytomas in Tuberous Sclerosis
- (2010) Darcy A. Krueger et al. NEW ENGLAND JOURNAL OF MEDICINE
- mTOR Inhibitor RAD001 (Everolimus) Has Antiangiogenic/Vascular Properties Distinct from a VEGFR Tyrosine Kinase Inhibitor
- (2009) H. A. Lane et al. CLINICAL CANCER RESEARCH
- Prevalence of subependymal giant cell tumors in patients with tuberous sclerosis and a review of the literature
- (2009) M. E. A. P. M. Adriaensen et al. EUROPEAN JOURNAL OF NEUROLOGY
- Equivalent benefit of mTORC1 blockade and combined PI3K-mTOR blockade in a mouse model of tuberous sclerosis
- (2009) Kristen Pollizzi et al. Molecular Cancer
- The TSC1–TSC2 complex: a molecular switchboard controlling cell growth
- (2008) Jingxiang Huang et al. BIOCHEMICAL JOURNAL
- Regression of Subependymal Giant Cell Astrocytoma With Rapamycin in Tuberous Sclerosis Complex
- (2008) Mary Kay Koenig et al. JOURNAL OF CHILD NEUROLOGY
- Identifying Optimal Biologic Doses of Everolimus (RAD001) in Patients With Cancer Based on the Modeling of Preclinical and Clinical Pharmacokinetic and Pharmacodynamic Data
- (2008) Chiaki Tanaka et al. JOURNAL OF CLINICAL ONCOLOGY
- Response of a Neuronal Model of Tuberous Sclerosis to Mammalian Target of Rapamycin (mTOR) Inhibitors: Effects on mTORC1 and Akt Signaling Lead to Improved Survival and Function
- (2008) L. Meikle et al. JOURNAL OF NEUROSCIENCE
- Tuberous sclerosis
- (2008) Paolo Curatolo et al. LANCET
- Possible mechanisms of disease development in tuberous sclerosis
- (2008) Jaroslaw Jozwiak et al. LANCET ONCOLOGY
- Subependymal giant cell astrocytoma (SEGA): Is it an astrocytoma? Morphological, immunohistochemical and ultrastructural study
- (2008) Anna M. Buccoliero et al. NEUROPATHOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started